BRAINSTORM CELL THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
Not required.
SIGNATURES
In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BRAINSTORM CELL THERAPEUTICS INC. | ||
| Date: April 1, 2024 | By: | /s/ Chaim Lebovits |
|---|---|---|
| | | Name: Chaim Lebovits |
| | | Title: Chief Executive Officer |
In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date | ||
|---|---|---|---|---|
| /s/ Chaim Lebovits | Chief Executive Officer | April 1, 2024 | ||
| Chaim Lebovits | (Principal Executive Officer) | |||
| /s/ Alla Patlis | Interim Chief Financial Officer and Controller | April 1, 2024 | ||
| Alla Patlis | (Principal Financial and Accounting Officer) | |||
| /s/ Irit Arbel | April 1, 2024 | |||
| Irit Arbel | Director | |||
| /s/ Nir Naor | April 1, 2024 | |||
| Nir Naor | Director | |||
| /s/ Jacob Frenkel | April 1, 2024 | |||
| Jacob Frenkel | Director | |||
| /s/ Anthony Polverino | April 1, 2024 | |||
| Anthony Polverino | Director | |||
| /s/ Uri Yablonka | April 1, 2024 | |||
| Uri Yablonka | Director | |||
| | | | | |
| /s/ Menghisteab Bairu | | | | April 1, 2024 |
| Menghisteab Bairu | | Director | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.